Investigators from the University of Manchester, Manchester, UK recently demonstrated a significant interaction between volume of identified calcifications and their mean radiotherapy (RT) dose in predicting survival in patients with non-small-cell lung cancer (NSCLC).
Age ≥60 years and ≥20 percent of normal lung volume receiving a radiation dose of ≥20 Gy (V20) are significant predictors of radiation pneumonitis (RP) in patients treated with intensity-modulated radiotherapy (IMRT) for lung cancer, a Chinese study has shown.
Reduction in gross tumour volume (GTV) during concurrent chemoradiation therapy (CRT) may be linked to worse overall survival (OS) in patients with locally advanced lung adenocarcinoma, according to a recent study reported at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC 2018).
Prognostic nutrition index (PNI) strongly predicts clinical outcomes in patients with locally advanced non-small-cell lung cancer (NSCLC), according to two studies presented at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer (WCLC 2018).
An updated 10-year analysis of the RTOG 0214 trial showed that the use of prophylactic cranial irradiation (PCI) improved disease-free survival (DFS) and reduced brain metastases, but failed to improve overall survival (OS) in patients with locally advanced non-small-cell lung carcinoma (LA-NSCLC).
Adding nintedanib to standard-of-care pemetrexed-cisplatin doublet chemotherapy does not improve progression-free survival (PFS) in patients with malignant pleural mesothelioma (MPM), the phase III LUME-Meso study has shown.
The anaplastic lymphoma kinase (ALK) inhibitor brigatinib demonstrated better progression-free survival (PFS) vs crizotinib among ALK-positive non-small-cell lung cancer (NSCLC) patients not previously treated with an ALK inhibitor.
Adaptive radiotherapy (RT) guided by 18F-FDG PET/CT functional imaging improves objective response rate (ORR) and survival in non-small-cell lung cancer (NSCLC) without increasing toxicity compared with conventional RT, a small study conducted in China has shown.
Adding cetuximab to afatinib does not improve overall survival (OS), progression-free survival (PFS) or objective response rate (ORR) in the first-line treatment of patients with advanced or recurrent non-small-cell lung cancer (NSCLC) harbouring classical sensitizing EGFR mutations.
Atezolizumab, when added to standard-of-care chemotherapy, significantly improves survival of patients with extensive-stage small-cell lung cancer (SCLC) in the first-line setting, according to results of the IMpower133 trial reported at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC 2018).
Not only does the CGRP* inhibitor galcanezumab show sustained efficacy in migraine patients, long-term treatment does not come with excess cardiovascular (CV) risk, according to studies presented at the AAN 2021 Annual Meeting.
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Among atrial fibrillation (AF) patients with clinically defined heart failure, catheter ablation yields greater survival gains, freedom from AF recurrence, and quality of life boost than does drug therapy, according to the results of the CABANA AF* substudy.
Combination treatment with three or more antihypertensive drugs provides greater blood pressure (BP)-lowering effect than monotherapy, results of a study have shown. However, the net benefit may be lessened when side effects are considered.